This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swede, H. Articles by Ip, C. Search for Related Content PubMed PubMed Citation Articles by Swede, H. Articles by Ip, C.

Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture

Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, New York

In the planning of future intervention trials using chemopreventive agents against lung cancer, it is critical to evaluate the effect on biomarkers implicated specifically in lung carcinogenesis. With the use of the H520 and H522 human lung cancer cell lines, the present study showed that treatment with selenium (in the form of methylseleninic acid) inhibited cell growth, arrested cell cycle progression at G₁, and induced apoptosis as a late event. Because H520 cells were more sensitive to selenium than H522 cells (IC₅₀ of MSA was 2.5 or 10 µM for H520 or H522 cells, respectively, at 24 h), a panel of nine cell cycle regulatory proteins known to be involved in G₁S transition was assessed by Western analysis using whole cell lysate from H520 cells. These nine proteins (DP1, cdc25A, cyclin A, cyclin B₁, cyclin D₁, cdk1, cdk5, p21^WAF1, and GADD153) have been reported previously by our laboratory to be modulated by MSA in human breast and prostate cancer cells. Our data showed that only four (DP1, cdc25A, p21^WAF1, and GADD153) of nine biomarkers produced the expected changes after treatment of lung cancer cells with MSA. This finding raises the possibility that the molecular targets sensitive to selenium modulation may be tissue specific. Thus, the selection of selenium biomarkers for evaluation in an intervention trial must be based on empirical data derived from the cancer cell type of interest.

This article has been cited by other articles:

				N. Joshi, L. L. Johnson, W.-Q. Wei, C. C. Abnet, Z.-W. Dong, P. R. Taylor, P. J. Limburg, S. M. Dawsey, E. T. Hawk, Y.-L. Qiao, et al. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk chinese population. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1046 - 1047. [Abstract] [Full Text] [PDF]